Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.57 |
| ▸ | FLT1 | P17948 | 5/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.57 |
| ▸ | KIT | P10721 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932214 | 0.87 | KDR (0.59) | KDRFLT1PDGFRBKIT | |
| SCHEMBL1930396 | 0.86 | KDR (0.60) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1930884 | 0.81 | KDR (0.54) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1930673 | 0.81 | KDR (0.56) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1930469 | 0.80 | KDR (0.65) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL4799898 | 0.76 | KDR (0.60) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1931149 | 0.76 | KDR (0.62) | KDRFLT1PDGFRBKIT | |
| SCHEMBL1930854 | 0.76 | KDR (0.67) | KDRFLT1PDGFRBKIT | |
| Hydrochloric Acid SCHEMBL6609546 | 0.73 | KDR (0.98) | KDRFLT1PDGFRBKIT | |
| SCHEMBL14104698 | 0.72 | KDR (0.59) | KDRFLT1PDGFRBKITMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034814-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG | 2009-03-19 | — | — | US | disclosed |
| US-7399761-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| EP-1387836-B1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDR 1/4885FLT1 2/4885PDGFRB 24/4885 |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDR 1/4885FLT1 2/4885PDGFRB 16/4885 |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | VEGFA, NR5A1, PGF | KDR 13/4885FLT1 5/4885PDGFRB 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.